UCSF and Zcube have entered into a new agreement to license UCSF-developed microtechnology and support early research into new ways to deliver oral medications directly to a targeted site in the body.
February 28, 2011
December 13, 2010
UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.
November 01, 2010
Anti-inflammatory drugs currently used to treat diseases such as rheumatoid arthritis may also help prevent cognitive decline after surgery, according to a new study led by researchers at UCSF and colleagues at Imperial College London.
November 01, 2010
Rapamycin, an FDA-approved drug prescribed to prevent the rejection of transplanted organs, has been shown for the first time to decrease excessive alcohol consumption, binge drinking, and alcohol-seeking behavior in rodents.
October 22, 2010
UCSF scientists have received two grants from the California Institute for Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure.
September 21, 2010
An inexpensive, hundred-year-old therapy for pain – aspirin – is effective in high doses for the treatment of severe headache and migraine caused by drug withdrawal, according to a new study by researchers with the UCSF Headache Center.
September 07, 2010
UCSF scientists will receive two grants totaling $15.1 million over the next five years to expand their research into how genes affect an individual’s response to medication and to strengthen a global network of researchers involved in these efforts.
July 15, 2010
A diabetes-care program designed by clinical pharmacy faculty in the UCSF School of Pharmacy Center for Self-Care has just launched in Northern California as a service for members of the California Public Employees Retirement System (CalPERS) with Blue Shield health coverage.
February 19, 2010
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the American Journal of Transplantation that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.
January 25, 2010
Some of the leading scientists in bioengineering, nanotechnology and pharmaco-genomics will gather on Tuesday, January 26, 2010 to discuss how to harness the tools of these emerging fields to develop new diagnostics and treatments for complex diseases.